Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model

Statistics in Medicine

Volumn 35, Issue 13, 2016, Pages 2195-2205

  Rogers, Jennifer K ^a   Yaroshinsky, Alex ^b   Pocock, Stuart J ^c   Stokar, David ^d   Pogoda, Janice ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Vital Systems Inc   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Mesoblast Limited   (Australia)

^e Celladon Corporation   (United States)

Author keywords

Dependent censoring; Heart failure; Joint frailty models; Recurrent events

Indexed keywords

CANDESARTAN; PLACEBO;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; FOLLOW UP; HAZARD RATIO; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; JOINT FRAILTY MODEL; MATHEMATICAL MODEL; PATIENT DROPOUT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME; VALIDATION PROCESS; MORTALITY; RECURRENT DISEASE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

DATA INTERPRETATION, STATISTICAL; HEART FAILURE; HOSPITALIZATION; HUMANS; MODELS, STATISTICAL; RECURRENCE; TREATMENT OUTCOME;

EID: 84964780815     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6853     Document Type: Article

References (26)

1. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. Journal of Cardiac Failure 2005; 11(8):567-575.
2. Anker SD, McMurray JJV. Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?. European Heart Journal 2012; 33:2764-2765.
3. Rogers JK, McMurray JJV, Pocock SJ, Zannad F, Krum H, Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation 2012; 126:2317-2323.
4. Rogers JK, Pocock SJ, McMurray JJV, Granger CB, Michelson EL, Östergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology with application to charm-preserved. European Journal of Heart Failure 2014; 16:33-40.
5. Borer JS, Böhm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez de Sa E, Swedberg K. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the shift study. European Heart Journal 2012; 33:2813-2820.
6. Glynn RJ, Buring JE. Ways of measuring rates of recurrent events. BMJ 1996; 312:364-367.
7. Greenwood M, Yule GU. An inquiry into the nature of frequency distributions representative of multiple happenings with particular reference to the occurrence of multiple attacks of disease or of repeated accidents. Journal of the Royal Statistical Society 1920; 83:255-279.
8. Andersen PK, Gill RD. Cox's regression model for countng processes: a large sample study. Annals of Statistics 1982; 10:1100-1120.
9. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distribution. Journal of the American Statistical Association 1989; 84(408):1065-1073.
10. Lin DY, Wei LJ. The robust inference for the cox proportional-hazards model. Journal of the American Statistical Association 1989; 84(408):1074-1078.
11. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 2007; 154(2):260-266.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94(446):496-509.
13. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000; 56:554-562.
14. Ghosh D, Lin DY. Marginal regression models for recurrent and terminal events. Statistica Sinica 2002; 12:663-688.
15. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics 2004; 60:747-756.
16. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J, Yusuf S. Effects of cadesartan on mortality and morbidity in patients with chronic heart failure: the charm-overall programme. The Lancet 2003; 362:759-766.
17. McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer M. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the charm-added trial. The Lancet 2003; 362:767-771.
18. Granfer CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Östergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the charm-alternative trial. The Lancet 2003; 362:772-776.
19. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological) 1972; 34(2):187-200.
20. Liu L, Huang X. The use of Gaussian quadrature for estimation in frailty proportional hazards models. Statistics in Medicine 2008; 27:2665-2683.
21. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabernberger R. SAS for Mixed Model (2nd edn). SAS Institute: Cary, NC, 2006.
22. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resychronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the comparison of medical therapy, pacing and defibrillation in heart failure (companion) trial. Circulation 2009; 119:969-977.
23. 2+-atpase un patients with advanced heart failure. Circulation 2011; 124:304-313.
24. Metcalfe C, Thompson SG. Wei, Lin and Weissfeld's marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome?. Statistical Methods in Medical Research 2007; 16:103-122.
25. Kibble WF. A two-variate gamma type distribution. Sankhyã 1941; 5:137-150.
26. Rogers JK, Jhund PS, Perez A, Böhm M, Cleland JG, Gullestad L, Kjekshus J, Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJV, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA trial (controlled rosuvastatin multinational trial in heart failure). Journal of the American College of Cardiology Heart Failure 2014; 2(3):289-297.